Iovance Biotherapeutics Inc - ESG Rating & Company Profile powered by AI
Comprehensive ESG assessment of Iovance Biotherapeutics Inc can be reached by logging in. This Disclosure score includes seventeen United Nations Sustainable Development Goals including: 'Clean Water & Sanitation', 'Responsible Production & Consumption' and 'Partnerships for the Goals'. Other corporations in the scoring industry group for Iovance Biotherapeutics Inc are displayed below.
Iovance Biotherapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.4; made up of an environmental score of 2.7, social score of 2.3 and governance score of 5.3.
3.4
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1186 | Simply Better Brands Corp | 3.5 | Medium |
1186 | Yunnan Baiyao Group Co Ltd | 3.5 | Medium |
1234 | Iovance Biotherapeutics Inc | 3.4 | Medium |
1234 | Cassava Sciences Inc | 3.4 | Medium |
1234 | Brickell Biotech Inc | 3.4 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Iovance Biotherapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Does Iovance Biotherapeutics Inc disclose current and historical energy intensity?
Does Iovance Biotherapeutics Inc report the average age of the workforce?
Does Iovance Biotherapeutics Inc reference operational or capital allocation in relation to climate change?
Does Iovance Biotherapeutics Inc disclose its ethnicity pay gap?
Does Iovance Biotherapeutics Inc disclose cybersecurity risks?
Does Iovance Biotherapeutics Inc offer flexible work?
Does Iovance Biotherapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Iovance Biotherapeutics Inc disclose the number of employees in R&D functions?
Does Iovance Biotherapeutics Inc conduct supply chain audits?
Does Iovance Biotherapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Iovance Biotherapeutics Inc conduct 360 degree staff reviews?
Does Iovance Biotherapeutics Inc disclose the individual responsible for D&I?
Does Iovance Biotherapeutics Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Iovance Biotherapeutics Inc disclose current and / or historical scope 2 emissions?
Does Iovance Biotherapeutics Inc disclose water use targets?
Does Iovance Biotherapeutics Inc have careers partnerships with academic institutions?
Did Iovance Biotherapeutics Inc have a product recall in the last two years?
Does Iovance Biotherapeutics Inc disclose incidents of discrimination?
Does Iovance Biotherapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Has Iovance Biotherapeutics Inc issued a profit warning in the past 24 months?
Does Iovance Biotherapeutics Inc disclose parental leave metrics?
Does Iovance Biotherapeutics Inc disclose climate scenario or pathway analysis?
Does Iovance Biotherapeutics Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Iovance Biotherapeutics Inc disclose the pay ratio of women to men?
Does Iovance Biotherapeutics Inc support suppliers with sustainability related research and development?
Does Iovance Biotherapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Iovance Biotherapeutics Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Iovance Biotherapeutics Inc involved in embryonic stem cell research?
Does Iovance Biotherapeutics Inc disclose GHG and Air Emissions intensity?
Does Iovance Biotherapeutics Inc disclose its waste policy?
Does Iovance Biotherapeutics Inc report according to TCFD requirements?
Does Iovance Biotherapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Iovance Biotherapeutics Inc disclose energy use targets?
Does Iovance Biotherapeutics Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Iovance Biotherapeutics Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Iovance Biotherapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.